Fundraising Fox
/Companies
Sign in

LoQus23

Cambridge, GB · 15 employees on LinkedIn · 5 known investors

Find your way into LoQus23

Sign up to see every warm intro you have to LoQus23

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the LoQus23 team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research. Founded in 2019 out of the Dementia Discovery Fund, it operates in the biotech and therapeutics sector.

BiotechDeep Tech

Founders & leadership

DRDavid Reynolds
David ReynoldsCo-founder & CEO
CBCaroline Benn
Caroline BennCo-founder & CSOCaroline Benn is co-founder and chief scientific officer of LoQus23 Therapeutics, which develops small-molecule therapeutics targeting DNA damage repair mechanisms for triplet repeat expansion diseases including Huntington's disease and myotonic dystrophy. She has a background in drug discovery research focused on neurodegenerative diseases.

Investors · 5

Novartis Venture Fundlisted by Novartis Venture FundBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · a partner's Signal profile · funding news · prnewswire.com · Not right? Tell us

SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20M

How we know: SV Health Investors's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

ForbionreportedNaarden

How we know: funding news · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us

Also in the syndicate · 1

SV Health Investors' Dementia Discovery Fund (DDF)

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 5

QuralisQurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Neuron23Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease. It aims to match patient subsets defined by genetic drivers with targeted therapies for conditions such as Parkinson's and Alzheimer's.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
ForbionA venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.

Companies working in the same space as LoQus23.

In the news

LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington's Diseasefinance.yahoo.com · Jan 2026LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's diseaseprnewswire.com · Oct 2024LoQus23 Therapeutics Raises £35M in Series A financingfinsmes.com · Oct 2024LoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fundprnewswire.com · Nov 2021

Frequently asked questions

What does LoQus23 do?
LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research. Founded in 2019 out of the Dementia Discovery Fund, it operates in the biotech and therapeutics sector.
Who founded LoQus23?
LoQus23 was founded by David Reynolds, Caroline Benn.
Who are LoQus23's investors?
LoQus23's investors include Dementia Discovery Fund, Novartis Venture Fund, SV Health Investors, Forbion.
Where is LoQus23 headquartered?
LoQus23 is headquartered in Cambridge, GB.